target therapies (biological drug, small molecules)
target therapies (biological drug, small molecules): describe the drug sruvival rate of the different approved drugs
Study summary
This is an observational study with drug to evaluate the drug survival of approved target therapies in atopic dermatitis. Patients affected by moderate-severe atopic dermatitis who will start therapy with approved target drugs (dupilumab, tralokinumab, upadacitinib, abrocitinib, baricitinib) for AD will be enrolled. Patients already on therapy with these drugs will also be included.
During the baseline and follow up visits, clinical and demographic data will be collected, according to ordinary clinical practice. Current or retrospective disease severity scores will also be collected.
Among the main: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Dermatology Life Quality Index (DLQI), Pruritus Numerical Rating Scale (NRS pruritus), Sleep Numerical Rating Scale (NRS sleep), Patient Oriented Eczema Measure (POEM).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age 18 years or older
* Diagnosed with moderate-to-severe atopic dermatitis (EASI\>24)
* Undergoing therapy (retrospective cohort) or undertaking systemic therapy with a biological drug or small molecules
* (for retrospective data) presence of at least one follow-up visit after the start of treatment for which clinical and demographic data were collected at baseline and follow-up visits.
* Signature of informed consent to the study and to the processing of personal data for the research
Exclusion Criteria:
* Patients under 18 years of age
* Patients who have undergone systemic therapy with a biological drug or small molecules for whom the start date of treatment is not available and/or no clinical-demographic data were collected at baseline and at follow-up visits.
* Absence of informed consent to the study and processing of personal data for research purposes.
Primary outcome measure(s)
drug survival evaluation — 1 year evaluate the 12-month drug survival rate, for each of the 5 biological drugs/small molecules under study.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
